I-Paclitaxel yendalo Cas 33069-62-4 Paclitaxel Manufacturers

Inkcazelo emfutshane:

Imveliso ephambili yeYunnan Hande kwintsimi yoxubo mayeza lichiza elikrwada le-paclitaxel.I-paclitaxel yendalo ye-Hande ithengiswe ngempumelelo kumazwe amaninzi nakwimimandla yaseMntla Melika, eYurophu naseAsia, yaba lishishini elimele kushishino.I-Hande Biotech ibonelela nge-Natural Paclitaxel Cas 33069-62-4.Ukufumana iinkcukacha ezithe vetshe, nceda uqhagamshelane ne-intanethi.


Iinkcukacha zeMveliso

Iithegi zeMveliso

Ulwazi ngeMveliso

Igama:Paclitaxel

Inombolo yeCAS:33069-62-4

Ifomula yemichiza:C47H51NO14

Iinkcukacha:99%-102%

Umbala:umgubo omhlophe okanye phantse omhlophe

Umthombo:Taxus yunnanensis,Taxus chinensis

Uhlobo:APIs

Ukusetyenziswa kwePaclitaxel

Isetyenziselwa amayeza kwaye isetyenziswe ngokubanzi kunyango lomhlaza wamabele, umhlaza we-ovarian, umhlaza wentloko kunye nentamo kunye nomhlaza wemiphunga ngokwezonyango.

Umjikelo wemveliso ye-Hande & umthamo

Umjikelo wemveliso:Iintsuku ezingama-45

Umthamo wemveliso yesandla:500kg / ngonyaka

Imbali ye-Hande GMP

1.Ngo-1996, inkqubo yomgangatho yasekwa kwaye yafunyanwa i-DMF.

2.Ngo-2004, uhlolo lwe-FDA kwisiza lufumene isatifikethi seCGMP.

3.Ngo-2009, i-semi-synthetic paclitaxel DMF kunye ne-CEP yendalo ye-paclitaxel yafunyanwa.

4.Ngo-2011, i-semi-synthetic paclitaxel CEP yafunyanwa.

5.Ngo-2012, iphumelele uhlolo lwe-TGA kwindawo, yafumana isatifikethi se-GMP, kwaye yaphumelela uhlolo lwe-FDA kwindawo.

6.Ngo-2013, yadlula indawo yeCGMP.

7.Ngo-2015, iIndiya yabhaliswa kwaye iJapan yabhaliswa.

Iinkonzo zethu

1.Iimveliso:Ukubonelela ngomgangatho ophezulu, izicatshulwa zezityalo ezisulungekileyo, imathiriyeli ekrwada yamayeza, kunye nabaphakathi bamayeza.

2.Iinkonzo zobugcisa:Izicatshulwa ezenziwe ngokwezifiso ezineenkcazo ezizodwa ngokweemfuno zabathengi.

Umzi-mveliso we-Hande

Yiba ngoyena mthengisi ubalaseleyo wezinto ezikrwada kunye namashishini anentembeko!

Wamkelekile ukuba uqhagamshelane nam ngokuthumela i-imeyile kumarketing@handebio.com


  • Ngaphambili:
  • Okulandelayo: